EXECUTIVE ENGAGEMENTS
OUTREACH
872
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
174
Interactions with Platform & by Email
PARTICIPANTS
33
Unique # Participated
VALIDATIONS
16
Responses Validated*
COMPETITORS
44
Responses Validated*
BRANDS
42
Responses Validated*
* Login for a full stack data experience
DATE
APR 2021
TABLES
165
PAGES
239
EDITION
8
PRICE
USD $4950
HIGHLIGHTS
Amid the COVID-19 crisis, the global market for Cancer/Tumor Profiling estimated at US$6.2 Billion in the year 2020, is projected to reach a revised size of US$11.6 Billion by 2027, growing at a CAGR of 9.3% over the analysis period 2020-2027. Immunoassays, one of the segments analyzed in the report, is projected to record a 9.1% CAGR and reach US$3.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Hybridization segment is readjusted to a revised 9.7% CAGR for the next 7-year period.
The Cancer/Tumor Profiling market in the U.S. is estimated at US$1.8 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2 Billion by the year 2027 trailing a CAGR of 8.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.5% and 7.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.6% CAGR.
In the global Next Generation Sequencing segment, USA, Canada, Japan, China and Europe will drive the 10.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$864.8 Million in the year 2020 will reach a projected size of US$1.7 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.3 Billion by the year 2027.
SELECT PLAYERS
Caris Life Sciences; Genomic Health, Inc.; Helomics Corporation; HTG Molecular Diagnostics, Inc.; Illumina, Inc.; Nanostring Technologies, Inc.; NeoGenomics Laboratories, Inc.; Oxford Gene Technology; Qiagen NV; Ribomed Biotechnologies, Inc.
SEGMENTS
» Application (Clinical Application, Research Application) » Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancer Types) » Technology (Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry, Other Technologies (Pyrosequencing and Sanger Sequencing))
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| Cancer/Tumor Profiling: Market Overview & Outlook |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| Increasing Incidence of Cancer Worldwide: Primary Growth Driver |
| EXHIBIT: Cancer Rates (100,000 People) in Select Countries: 2021 |
| EXHIBIT: Estimated New Cancer Cases & Deaths in the US by Sex: 2020 |
| EXHIBIT: Estimated Number of New Cancer Cases in Men by Cancer Type: 2020 |
| The United States: Characterized by Higher Incidence of Cancer |
| EXHIBIT: Estimated New Cancer Cases & Deaths in the US by Sex: 2020 |
| EXHIBIT: Estimated New Cases for Selected Cancers in the US by State: 2020 |
| Enhanced Use of Biomarkers in Tumor Profiling Bodes Well |
| Cancer Research & Funding Initiatives Augment Market Prospects |
| Growing Role of Personalized Medicine Augurs Well |
| Advances in Point-of-Care Cancer Diagnostics to Accelerate Uptake |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Cancer/Tumor Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Cancer/Tumor Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Cancer/Tumor Profiling by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Immunoassays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Hybridization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Mass Spectrometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Melanoma Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Melanoma Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Melanoma Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Clinical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Clinical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Clinical Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Research Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Cancer/Tumor Profiling by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Cancer/Tumor Profiling by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Cancer/Tumor Profiling by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 44 |
Is the U.S. Still a Better Global Barometer than China?
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com